Motehaver Alireza Nemati, Sheida Fateme, Javadinia Seyed Alireza, Behzadi Behnaz, Afshar Saeid, Khezrian Ali, Ganjuri Mostafa, Eslah Shadi, Mokhles Parisa, Keshtpour Amlashi Zahra, Akbari Mohammad Esmaeil
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Chonnam Med J. 2025 May;61(2):63-74. doi: 10.4068/cmj.2025.61.2.63. Epub 2025 May 23.
Breast cancer is one of the most common causes of death all over the world. Therapeutic options applied to the patients include surgery, chemotherapy, and radiotherapy. However, far advanced disease often leads to chemoresistance and toxicity. Innovative therapies are needed to address these challenges. Melatonin has the potential to prevent and treat cancer, as it has been revealed in numerous clinical studies. Melatonin is a nontoxic agent that is mostly produced in the pineal gland, inducing various mechanisms of action such as the induction of apoptosis, antiangiogenic, antiproliferative, and metastasis-inhibitory effects. Therefore, melatonin increases therapeutic sensitivity when combined with conventional medication in breast cancer. Melatonin (3-20 mg/day) may reduce breast cancer cell growth in preclinical studies and enhance chemotherapy efficacy. Small human trials suggest potential benefits, but larger studies are needed. Higher doses (≥20 mg/day) are sometimes used alongside chemotherapy. This manuscript reviews research that has demonstrated the antitumor properties of melatonin, thereby focusing on its actions on angiogenesis, apoptosis, metastasis, and antiproliferative properties. We also discuss recent advances in the understanding of the actions of melatonin on epigenetic mechanisms (especially DNA methylation) and telomere length. The data in this review were obtained from journal articles up to May 2024. Regarding the study, Google Scholar and ScienceDirect were used as engines to search for open access. We searched the ISI, Pubmed and Scopus as valid external databases, and as internal databases, ISC and Iran medex. By finding mean keywords such as 'breast cancer', 'estrogen', 'melatonin', 'cell death', 'cell proliferation', 'telomerase' and 'DNA methylation', we reached to the formula with maximum collectivity in searching, then equivalent terms were found by Mesh database. The review also covers recent clinical investigations of melatonin in breast cancer.
乳腺癌是全球最常见的死因之一。应用于患者的治疗选择包括手术、化疗和放疗。然而,晚期疾病往往导致化疗耐药性和毒性。需要创新疗法来应对这些挑战。褪黑素具有预防和治疗癌症的潜力,这已在众多临床研究中得到证实。褪黑素是一种无毒物质,主要由松果体产生,可诱导多种作用机制,如诱导细胞凋亡、抗血管生成、抗增殖和抑制转移作用。因此,褪黑素与乳腺癌常规药物联合使用时可提高治疗敏感性。在临床前研究中,褪黑素(3 - 20毫克/天)可能会减少乳腺癌细胞生长并增强化疗疗效。小型人体试验显示出潜在益处,但仍需要更大规模的研究。有时会与化疗一起使用更高剂量(≥20毫克/天)。本手稿回顾了已证明褪黑素抗肿瘤特性的研究,从而重点关注其对血管生成、细胞凋亡、转移和抗增殖特性的作用。我们还讨论了在理解褪黑素对表观遗传机制(尤其是DNA甲基化)和端粒长度作用方面的最新进展。本综述中的数据来自截至2024年5月的期刊文章。关于这项研究,谷歌学术和科学Direct被用作搜索开放获取文献的引擎。我们搜索了ISI、PubMed和Scopus作为有效的外部数据库,以及ISC和伊朗医学数据库作为内部数据库。通过查找“乳腺癌”、“雌激素”、“褪黑素”、“细胞死亡”、“细胞增殖”、“端粒酶”和“DNA甲基化”等关键词,我们得出了搜索中具有最大全面性的公式,然后通过医学主题词数据库找到了等效术语。该综述还涵盖了褪黑素在乳腺癌方面的最新临床研究。